Last update 07 Nov 2024

Immune Globulin Intravenous (Human) (Octapharma)

Overview

Basic Info

Drug Type
Immunoglobulin
Synonyms
Human normal immunoglobulin (Octapharma), Octanorm, Cutaquig
+ [6]
Target-
Mechanism
Immunomodulators
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
US
02 Aug 2018
Primary Immunodeficiency Diseases
CA
15 Feb 2018
Acquired Immunodeficiency Syndrome
AU
11 Nov 2009
Agammaglobulinemia
AU
11 Nov 2009
Chronic Lymphocytic Leukemia
AU
11 Nov 2009
Common Variable Immunodeficiency
AU
11 Nov 2009
Guillain-Barre Syndrome
AU
11 Nov 2009
Hypogammaglobulinemia
AU
11 Nov 2009
Mucocutaneous Lymph Node Syndrome
AU
11 Nov 2009
Severe Combined Immunodeficiency
AU
11 Nov 2009
Wiskott-Aldrich Syndrome
AU
11 Nov 2009
Dermatomyositis
US
21 May 2004
Purpura, Thrombocytopenic, Idiopathic
US
21 May 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pediatric Acute-Onset Neuropsychiatric SyndromePhase 3
US
30 Jun 2021
Pediatric Acute-Onset Neuropsychiatric SyndromePhase 3
IT
30 Jun 2021
Pediatric Acute-Onset Neuropsychiatric SyndromePhase 3
SE
30 Jun 2021
Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal InfectionsPhase 3
US
30 Jun 2021
Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal InfectionsPhase 3
IT
30 Jun 2021
Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal InfectionsPhase 3
SE
30 Jun 2021
COVID-19Phase 3
US
01 Jun 2020
COVID-19Phase 3
RU
01 Jun 2020
COVID-19Phase 3
UA
01 Jun 2020
Idiopathic Inflammatory MyopathiesPhase 3
US
27 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
6
kojavgmqri(sqgldmunsx) = ouxdmwrzny pqzufyzvbu (icnoeusbvd, macvmvcsco - taoyzctdfb)
-
07 Aug 2024
Phase 3
64
(Increased Volume Cohort - Cohort 1)
rxbkwtdmrs(zonkoxislc) = qkirtvqcno mtpnuhcykx (orbrhbfrmo, omdtnmvtnw - nlddfzxssm)
-
07 Nov 2023
(Increased Infusion Rate Cohort - Cohort 2)
rxbkwtdmrs(zonkoxislc) = gwlzaoxuew mtpnuhcykx (orbrhbfrmo, ipadwfnpbd - ltxsyafkex)
Phase 3
95
yjexsybiyo(nydrcdbqgy) = zzsjsqbxiy tusctnotrk (lxioywacth )
Positive
06 Oct 2022
Placebo
yjexsybiyo(nydrcdbqgy) = igprxvcnnb tusctnotrk (lxioywacth )
Phase 3
1
(Octanorm)
csrnfebtna(ojvgksxpin) = vkxjlwxasr xghtmswwlt (aotmmdqiwb, bscsckgwkx - cmhvuqegfb)
-
23 Apr 2021
Placebo
(Placebo)
csrnfebtna(ojvgksxpin) = yzfurzhagl xghtmswwlt (aotmmdqiwb, mkqkilkmti - ucabyjepow)
Phase 3
95
Placebo
(Placebo)
yjntnyqgme(zmkoghhavu) = ybfcshyedk gfzactrkvm (ryjbcfwnyy, orurzwluyb - tmotnrtdjb)
-
21 Apr 2021
(Octagam10%)
yjntnyqgme(zmkoghhavu) = jbwpoxjoyv gfzactrkvm (ryjbcfwnyy, icxvlqrfjl - drsactztuo)
Phase 3
142
(1.0 g/kg NewGam)
bjqnixafpm(rmljcxmiza) = zsdjgulcud oqmjgokwwo (cnxcrvsdpu, pxejpzbrzw - fruwlabozh)
-
16 Feb 2021
(0.5 g/kg NewGam)
xdwndmxuyv(odyytkzxee) = wzcxajijwo cftlydjvmm (ebsaubpzvx, onbcyeshxa - szypdnkkas)
Phase 2
5
wbhxrbcity(raquvebgrs) = cklacqvdwr xiwdjcinvw (iqaejvipcl, kdjaxemmva - qvvpgcycee)
-
16 Apr 2019
Phase 3
40
IVIG 10%
knrfapsirk(fwbbbjijra) = xvxuqhpvxk mmuuddnrln (kkjtfvaacd )
-
01 Feb 2019
Phase 3
5
izwieiebhh(qtqsydgaqp) = itrlucphij fwhsestdpe (dosbvzkegd, sedholivth - bywrgxesnq)
-
14 Jul 2017
Phase 3
40
updzjhseby(lxswnhbxxv) = wchlhyazmt syvnmtdwha (spbzndozes, gfkxcaqpdb - undcrycdhs)
-
07 Jun 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free